Mevion and C-RAD Release Integration for Improved Treatment Quality in Proton Therapy

Mevion Medical Systems and C-RAD have announced the integration between the C-RAD Catalyst PT and the MEVION S250i Proton Therapy System. The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.
 
C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy – the Catalyst PT, based on the patented Catalyst technology and software.
 
Maastro Proton Therapy, equipped with the MEVION 250i Proton Therapy System, and C-RAD announced a strategic agreement in 2018 to install the Catalyst PT at the center. C-RAD and Mevion co-developed a solution based on both companies’ products that allows a high level of integration to enhance user comfort and patient safety.
 
Guided by the expertise and requirements of Maastro Proton Therapy, the two industry partners focused on developing the interface required to support a seamless workflow, including automatic patient position correction and monitoring throughout the entire treatment process.
 
Tina Yu, chief executive officer of Mevion Medical Systems, said: “In keeping with Mevion’s commitment to providing products and services, we are proud to partner with C-RAD to offer the most advanced and fully integrated proton patient positioning platform to our customers.”
 
The installation of the Catalyst PT at Maastro Proton Therapy was commissioned over the summer and was released for clinical operation in August. Maastro Proton Therapy will be deploying the Catalyst PT especially for thoracic tumor indications treated on the Mevion system.
 
Geert Bosmans, managing director of Maastro Proton Therapy said: “To provide our patients with an improved high-quality treatment plan we installed the C-RAD surface tracking system in our center. We will use it to accurately position and continuously monitor our patients during treatment for increased high precision radiation therapy.”
 
The Catalyst PT system is now available to current and future Mevion customers.
 
“Accurate patient positioning before and monitoring during treatment is crucial in high precision radiation therapy. This development is driving the interest for our leading surface tracking solutions,” said Tim Thurn, CEO and president of C-RAD AB. “User experience and workflow optimization is becoming increasingly important for our customers. C-RAD’s objective has always been to define the benchmark in usability and workflow integration. With this project, C-RAD and Mevion stepped up to mark the new standard.”
 
The Maastro Proton Therapy started treating patients with protons in February 2019. It is the first Mevion system in Europe and because of the compact Mevion technology; it is fully integrated into an existing radiotherapy center, Maastricht Radiation Oncology (Maastro).
 
Mevion Medical Systems Inc. provides compact proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Mass., with a presence in Europe and China.

C-RAD develops solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the United States, and C-RAD GmbH in Germany. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm